IntroductIon 1 novartis institutes for BioMedical research, novartis Pharma aG, Basel, switzerland. 2 novartis institutes for BioMedical research, cambridge, Ma, Usa. 3 current address: high throughput screening resource center, the rockefeller University, new York, nY, Usa.
M ethicillin-resistant StaphylococcuS aureuS (Mrsa) infections are a rising health problem that has lent some urgency to the search for new antibiotics. 1 Most compounds currently in clinical trials, however, are derived from known chemical classes and address molecular mechanisms against which resistance is already observed in clinical practice. 2 thus far, variants of two general strategies have been employed to discover novel antibiotics: target-based screening using mostly biochemical assays and whole-cell screening focusing on antibacterial activity against a particular pathogen. Both strategies have their challenges 3 : target-based screens focus on a particular cellular target, most often an enzyme, for which essentiality is assumed or has been established. although potent inhibitors can be found, 4 compounds often lack the necessary cellular activity in a suitable spectrum of bacterial pathogens. Whole-cell screening strategies focus on growth inhibition, thereby establishing permeability from the start. the challenge is then to detect useful hits among thousands of nuisance compounds that affect unspecific, cytotoxic mechanisms. furthermore, the identification of the molecular target and the mechanism of action (Moa) can be cumbersome, even though examples exist where this has been achieved. 5 assays have been devised to determine the mechanism of action that links a phenotype such as bacterial growth with an antibacterial target. these methods rely on the titration of the intracellular enzyme level through, for example, regulated gene expression 6, 7 or antisense rna silencing. 8, 9 in these studies, decreased expression of the target enzyme led to an increased sensitivity toward inhibitors if the enzyme was essential for bacterial growth or survival. however, the challenge remains to detect weak activities within large numbers of hits, especially when these assays can be difficult to miniaturize.
We adapted this strategy for the primary screen of 1.3 million compounds in 1536-well plate format. We report here on its application to the discovery of inhibitors of the mevalonatedependent isopentenyl pyrophosphate (iPP) biosynthetic pathway in gram-positive bacteria, especially S. aureus. the combination of pathway-sensitized strains with rapid follow-up through high-throughput "cherry-picking" and profiling of 10 000 compounds allowed the completion of this screen in less than 2 months. the mevalonate pathway is used in all eukaryotic organisms to synthesize iPP, the central precursor of isoprenoids. in bacteria, the gram-positive pathogens S. aureus, Streptococcus pneumoniae, and Enterococcus faecalis have been shown to exclusively rely on the mevalonate-dependent pathway for iPP synthesis. [10] [11] [12] in this pathway, three molecules of acetyl coenzyme a (acetyl-coa) condense to the intermediate 3-hydroxy-3methylglutaryl-coa (hMG-coa), and the second condensation is catalyzed by the enzyme hMG-coa synthase (Mvas). a reduction of the intermediate by hMG-coa reductase (Mvaa) yields mevalonic acid, for which the pathway is named. Mevalonate is then doubly phosphorylated by two kinases (MvaK1, MvaK2), decarboxylated, and dehydrated (MvaD) to form iPP ( Fig. 1) .
in a previous study, 13 we had constructed three strains of S. aureus in which each of the mevalonate pathway genes is regulated by an isopropyl-β-D-thiogalactopyranoside (iPtG)inducible promoter. We had used Dna microarrays to profile the transcriptional effects of downregulating the components of the mevalonate pathway in S. aureus and demonstrated that decreased expression of the mevalonate pathway leads to widespread downregulation of primary metabolism genes and an upregulation in virulence factors and cell wall biosynthetic determinants. the translation of these findings into drug discovery required a strategy that would overcome the hurdle of de-convoluting tens of thousands of hits. exploiting the sensitized nature of these strains at various steps along the screening flowchart allowed us to rapidly identify specific inhibitors of mevalonate pathway enzymes.
as an early pathway enzyme, the hMG-coa synthase (Mvas) was chosen as a first target for high-throughput screening (hts). Because the pathway is anterograde, meaning downstream enzymes are upregulated in response to Mvas deficiency, synergism could be expected upon inhibition of both Mvas and a second pathway enzyme. transcriptional regulation has been shown to occur at the level of mvaK1/D/K2, which are regulated as one operon. We therefore proceeded with a second hts using a strain that regulated these genes. We show that miniaturization of a bacterial growth assay with a simple optical density readout to a 384-well format and even to a 1536-well format is possible with high data quality.
MAterIALS And MethodS

Materials
Medium (nZYM, broth, and agar) was prepared in-house. iPtG was obtained from acros organics (fisher scientific, Wohlen, switzerland). erythromycin was purchased from sigma-aldrich (st. louis, Mo). Phosphate-buffered saline (PBs) was obtained from invitrogen (carlsbad, ca). Microplates (384-well black polystyrene, clear bottom and 1536-well black polystyrene, clear bottom) were purchased from Greiner (frickenhausen, Germany). rn4220 was obtained from narsa (network on antimicrobial resistance in Staphylococcus aureus, chantilly, Va).
Generation of mutants
Mevalonate pathway mutants were generated that placed the genes mvaS (hMG-coa synthase), mvaA (hMG-coa reductase), and mvaK1 (mevalonate kinase) under the control of an iPtG-inducible Pspac promotor, as described previously. 13 Briefly, for each gene subjected to promoter exchange, the 5′ portion of the corresponding gene was cloned into the integration plasmid pMUtin, 14 which is nonreplicative in S. aureus but can be manipulated and propagated in Escherichia coli. Dna fragments were amplified from S. aureus rn4220 genomic Dna and cloned into the hindiii and ecori sites in pMutin, which are located downstream of the Pspac promoter. Upon sequence confirmation, the resulting plasmids were transformed into S. aureus rn4220 cells, and the plasmid integrants based on homologous recombination were selected on agar plates containing 5 µg/ml of erythromycin and 100 µM iPtG. the S. aureus mevalonate pathway mutants for mvaS, mvaA, and mvaK1 were designated rn4220spacmvas, rn4220spacmvaa, and rn4220spacmvaK, respectively. an S. aureus strain with regulatable glmU gene was constructed in the same way and named rn4220spacglmU.
MvaS strain growth assay
inoculum of the rn4220spacmvas strain was prepared by suspending two colonies from an overnight culture grown on nZYM agar in 25 ml 1× PBs. the hts was performed in a 384-well format on workstations with an average of 300 plates per day. Using a Multidrop combi (thermo fisher scientific, Waltham, Ma), 3.5 µl of the inoculum cell suspension was transferred to each well of a 384-well microplate that contained premixed 1.5 µl of a 2-mM compound solution (in 90% DMso/ water) and 25 µl nZYM (supplemented with 6 µM iPtG and 6 mg/l erythromycin). the microplate was then incubated at 37 °c for 8 h. the growth of the bacterial cells was monitored by recording the optical density at 595 nm (oD595) using an enVision plate reader (Perkinelmer, Waltham, Ma).
MvaK strain growth assay
inoculum of the rn4220spacmvaK strain was prepared by suspending two colonies from an overnight culture grown on nZYM agar in 25 ml 1× PBs. the hts was performed in a 1536-well format on an ultra-hts (uhts) system by rts (rts life science, Manchester, UK) with an average of 100 plates per day. Using a synquad dispenser (Zinsser analytic, frankfurt, Germany), 1.2 µl of the inoculum cell suspension was transferred to a 1536-well polystyrene black microclear plate containing 6.8 µl of nZYM (supplemented with 12 µM iPtG and 6 mg/l erythromycin) mixed with 40 nl of a 2-mM compound solution in 90% DMso/water. the microplate was then incubated at 37 °c for 8 h. the growth of the bacterial cells was monitored by recording the optical density at 595 nm (oD595) using an enVision plate reader (Perkinelmer).
S. aureus profiling assays
inoculum of the strains rn4220spacmvaa or rn4220 spacg-lmU was prepared by diluting two fresh overnight cell colonies from an agar medium Petri dish in 25 ml 1× PBs. the bacterial growth assay followed the procedure as described for the Mvas assay, with an incubation time of 12 h.
Data analysis
Primary screening data were corrected for plate positiondependent systematic response errors by robust local regression modeling, a plate data correction method that is implemented among several other plate-wise or batch-wise data normalization approaches in our in-house screening data processing system. 15 the Z′ factor was employed as a measure of the dynamic range combined with the standard deviations. 16 an assay can be considered robust for 0.4 < Z′ < 1.
Enzyme inhibition assay
the Mvas reaction was conducted in a 96-well ultraviolet (UV) half-area plate (catalog 3679; corning, corning, nY). in a standard assay, an 80-µl Mvas enzyme solution was made in the reaction buffer (100 mM tris hcl [ph 7.6], 50 mM Kcl, 10 mM Mgcl 2 , 0.01% triton X-100, 100 µg/ml bovine serum albumin [Bsa], and 1 mM tris[2-carboxyethyl]phosphine [tceP]). the reaction was initiated by the addition of 20 µl of the substrate cocktail containing 1750 µM acetyl-coa and 15 µM acetoacetyl-coa diluted in the reaction buffer. the final substrate concentrations were 350 µM for acetyl-coa and 3 µM for acetoacetyl-coa. When testing compounds for their inhibitory activities, the enzyme solution was preincubated with 1 µl compound solution for 10 min before the substrate cocktail was added. the reaction was monitored for absorbance at 300 nm for 40 min in a spectraMax Plus plate reader (Molecular Devices, sunnyvale, ca).
Measurement of antibacterial activity
S. aureus (atcc 29213), E. faecalis (atcc 29212), E. coli (atcc 25922), S. pneumoniae (atcc49619), and Bacillus subtilis (atcc6633) were assayed for sensitivity to antibacterials via a standard broth microdilution method (clinical and laboratory standards institute [clsi]). 17 Briefly, cultures were grown on blood agar plates (remel, lenexa, Ks) overnight at 37 °c and then used to inoculate tubes containing 5 ml of Mueller hinton broth (Difco MhB, BD, franklin lakes, nJ, Usa). after a 4-to 5-h incubation at 37 °c, the culture was adjusted with sterile saline (nacl 0.86%) to a turbidity of 0.5 Mcfarland standard. assays were performed in sterile plastic 96-well microtiter trays with round-bottom wells. the wells of the assay plate were filled with 100 µl of MhB, and 1 µl of a compound dilution series was added to the medium. then, 1.5 µl of the diluted bacterial culture was added to the wells, and the plates were incubated for 20 to 24 h at 37 °c in air. Minimum inhibitory concentration (Mic) values were determined by visual inspection of the plates. the Mic was defined as the lowest drug concentration causing complete suppression of visible bacterial growth.
Mevalonate rescue
for testing the effect of mevalonate on the antibacterial activity of the screening hits, 1 ml of melted Muller hinton agar, either with or without 0.5 mM mevalonate, was mixed with 70 000 cfu of S. aureus (atcc 29213) or plated in each well of a 12-well tissue culture plate. after the agar had solidified, 1 µl of compound (0.8 mg/ml for tetracycline, 3.2 mg/ml for hymeglusin, 12.8 mg/ml for compounds 1 and 2, all dissolved in DMso) was spotted on top of the agar. the plate was then incubated at 37 °c for 16 h, and the result was recorded with a Bio-rad (hercules, ca) Gel Doc system.
reSuLtS
Construction of regulated mevalonate pathway S. aureus strains
S. aureus mutants were generated in which each mevalonatedependent iPP biosynthetic pathway gene was placed under the control of the iPtG-inducible Pspac promoter. 13 the 5′ portion of the target gene was cloned into the integration plasmid pMUtin, propagated in E. coli, and then transformed into S. aureus rn4220. three strains were produced: rn4220spacmvas, which regulates hMG-coa synthase (mvaS); rn4220spacmvaa, which regulates hMG-coa reductase (mvaA); and rn4220 spacmvaK, which regulates mevalonate kinase (mvaK1). MvaK1 is the first gene in a tricistronic transcript containing mvaK1-mvaD-mvaK2. its regulation affects the expression not only of mevalonate kinase (mvaK1) but also of mevalonate diphosphate decarboxylase (mvaD) and phosphomevalonate kinase (mvaK2). it could be demonstrated that expression of these genes and, in turn, growth of the respective strains depended on iPtG induction, confirming the essentiality of these genes.
Optimization and assessment of a 384-well MvaS assay
With the strains in hand, we wanted to test their suitability for hts in a miniaturized format. the strategy to use engineered bacterial strains sensitized toward inhibitors of an individual biosynthetic enzyme is based on the hypothesis that bacterial growth is proportional to the level of enzyme inhibition. absorbance, or optical density at 595 nm (oD595), is a direct measure of cell density. as optical density does not rely on any indirect measurement or amplification step, it is a very robust readout that is insensitive to compound interference. to allow for a 1.3-million compound screen and rapid characterization of all hits, we optimized an oD assay initially to a 384-well and later to a 1536-well format.
first, it was established that, in 384-well plates, the optical density measured at 595 nm was representative of bacteria culture density. Miniaturization from a 96-well format to a 384well format still allowed for growth conditions where a linear fit could be used to translate the oD counts into bacteria number or culture dilution ( Fig. 2A) . Under iPtG concentrations between 2.5 µM and 1 mM and after a 3-to 4-h lag phase, the bacteria grew in an iPtG concentration-dependent manner (Fig. 2B) .
to balance assay sensitivity with assay window, we decided to use a low iPtG concentration of 5 µM. a relatively short growth incubation time of 8 h was chosen to limit growth of any non-iPtG-dependent bacteria population. the cells divided at a constant rate, influenced by the growth medium, the iPtG concentration, and the incubation time. the bacteria inoculum density influenced the steepness of the exponential log phase and therefore the dynamic range of the assay.
it is known that S. aureus can take up mevalonate from the medium and bypass the mevalonate-dependent iPP biosynthetic pathway. 18 increasing mevalonate concentrations in the medium in the absence of iPtG resulted in a growth curve comparable to that observed with maximal iPtG induction (Fig. 2c) . this rescue through mevalonate feeding confirms that the observed growth retardation in the mutant strain is due to a specific defect of the mevalonate pathway rather than due to a general reduced fitness of the organism.
With the expression of mvaS under the control of an iPtGinducible promoter, the intracellular amount of hMG-coa synthase (Mvas) is dependent on the iPtG concentration. inhibitors of hMG-coa synthase should display greater antibacterial potency under low iPtG conditions due to the reduced level of cellular hMG-coa synthase. a known hMG-coa synthase inhibitor, hymeglusin, 19, 20 was therefore tested under exponential growth conditions. a clear dependency of the observed ic 50 value on the iPtG concentration could be observed (Fig. 2d) , and the absolute ic 50 value is dependent on the assay conditions.
MvaS screen
in total, 1.3 million compounds were tested at a final concentration of 10 µM under low iPtG conditions (5 µM iPtG). the statistical quality of the hts was very good, as demonstrated by an average Z′ value of 0.6 ± 0.13 (n = 3718); Figure 3 shows typical data from the screen. the compound activity parsed into two clear distributions, one around zero activity and one around -100% activity (Fig. 4A) . a 50% inhibition cutoff was chosen as a midpoint between the two populations, which resulted in 24 702 primary hits (2% hit rate). such high hit rates are usually a challenge for follow-up and often require a cheminformatics-driven filtering of the hit list. for phenotypic assays, this is especially unsatisfactory because little additional information besides the primary screening data can be used to guide the selection, and enrichment of desired hits over undesired ones can be expected. We intended to use the iPtG-dependent potency shift as a diagnostic tool to distinguish pathwayspecific inhibitors from unspecific growth inhibitors. this strategy required cherry-picking and arraying of >20 000 compounds in multiple concentrations. We have recently reported a highthroughput cherry-picking system that allows rapid, iterative follow-up of large hit lists. 21 the primary hits were thus profiled in four concentrations under two different iPtG conditions (5 µM and 1 mM). the ratio of ic 50 under both iPtG conditions values was used to select compounds with apparent selectivity for the Mvas enzyme. a total of 1558 primary hits displayed an iPtG-dependent ic 50 ratio of fivefold or greater (i.e., an ic 50 ratio similar to the reference compound hymeglusin; Fig. 4B) . an additional 1453 very potent compounds (<330 nM ic 50 ) were also selected despite not showing an iPtG-dependent potency shift because a potency shift might not have been detectable at the limited concentration range tested. all selected compounds were tested in 8-point concentration-response curves (crc) in triplicate under both high (1 mM) and low (5 µM) iPtG concentrations. in total, 1201 hits displayed an iPtG-dependent ic 50 ratio of fivefold or greater and were considered confirmed hits.
Optimization and assessment of a 1536-well MvaK assay
next, an assay for mevalonate kinase (mvaK1), mevalonate diphosphate decarboxylase (mvaD), and phosphomevalonate kinase (mvaK2) was developed using the rn4220spacmvaK strain. encouraged by the high data quality in the Mvas screen, we tried to miniaturize the MvaK assay even further to a 1536well format. linearity of bacteria cell number to oD595 signal was well maintained in this high-density format (Fig. 5A) . the assay was run under low iPtG conditions (10 µM) and with a short incubation time (8 h) to reduce non-iPtG-dependent populations ( Fig. 5B) . Because the enzyme encoded by mvaK was downstream of the step inhibited by hymeglusin, the inhibition of the iPtG-inducible mvaK strain by hymeglusin was insensitive to the iPtG concentration (Fig. 5c) .
MvaK Screen
similar to the Mvas screening strategy, 1.3 million compounds were tested at a low iPtG concentration (10 µM), and the primary hit list with a 50% inhibition cutoff contained 10 904 primary hits (0.9% hit rate). the quality of the hts was excellent, as demonstrated by an average Z′ value greater than 0.7 ± 0.08 (n = 1003). as previously observed in the Mvas screen, the compound activity in the 1536-well MvaK assay parsed into two distribution groups, around zero activity and around −100% activity. a 50% inhibition cutoff resulted in 4285 remaining primary hits, which were tested for MvaK specificity in an 8-point crc under two iPtG conditions (10 µM and 1 mM). a total of 277 hits displayed an iPtG-dependent ic 50 ratio of 2.5-fold or greater and were considered confirmed hits (Fig. 5d) .
Profiling and characterization of hits
hits from both S. aureus hts screens were profiled in bacterial growth assays. an S. aureus strain sensitized for an enzyme from an unrelated pathway, GlmU (n-acetylglucosamine-1-phosphate uridyl transferase), 22 was used to ascertain specificity for the mevalonate pathway. any hit showing iPtG-dependent potency on this strain likely interfered with the promoter rather than with the enzyme. the target specificity was further confirmed by testing hits on the mvaA strain rn4220spacmvaa, using protocols similar to the ones described. Because downregulation of mvaS or mvaK1-mvaD-mvaK2 has been demonstrated to influence expression levels of mvaA, it is conceivable that both hit lists contain compounds that have hMG-coa reductase (Mvaa) as a molecular target.
Profiling resulted in 59 compounds selectively active against the regulated hMG-coa synthase strain, as well as 42 compounds selectively active against the MVa kinase/MVaP kinase/ MVaPP decarboxylase strain. Profiling data for two hit compounds are shown in table 1. Both compounds 1 and 2 show an iPtG-dependent potency in the Mvas assay but not in control assays. they show a similar profile as the hMG-coa synthase inhibitor hymeglusin. in contrast, reference antibiotics that work through other mechanisms show no iPtG-dependent potency. final proof of target inhibition was achieved when both compounds were shown to inhibit hMG-coa synthase in an enzymatic assay with ic 50 = 0.7 µM for compound 1 and ic 50 = 0.4 µM for compound 2.
Measurement of antibacterial activity
following identification of hits with antibacterial activity on the S. aureus strain rn4220spacmvas, Mics were determined by a standard broth micro-dilution assay 17 on a panel of gram-positive and gram-negative species. the results shown in table 2 demonstrate the potent antimicrobial activities of two representative compounds against the gram-positive species S. aureus and S. pneumoniae. importantly, the compounds have no measurable/weak antibacterial activity against the gram-negative E. coli (a tolc pump knockout mutant for increased cellular assessibility) and the gram-positive B. subtilis, which does not rely on the mevalonate pathway for iPP production. it should be noted that these compounds lack antimicrobial activity against the gram-positive, mevalonate pathway-dependent pathogen E. faecalis, which is mostly likely due to the strong permeation barrier associated with the cell wall of this organism.
Mevalonate rescue
S. aureus can take up mevalonate from the medium and compensate for deficiencies in endogenous synthesis. 18 as depicted in Figure 2c , mevalonate feeding was able to overcome the growth defect resulting from underexpression of Mvas. to confirm that compounds 1 and 2 act specifically on the mevalonate pathway, we compared their antibacterial activity using an agar-based bacterial growth assay (Fig. 6) . in the absence of mevalonate, compounds 1 and 2 strongly inhibited S. aureus growth, as evidenced by the large clear areas associated with the application of the compounds. in contrast, in the presence of mevalonate, there were no clear zones surrounding the center spots where the compounds were applied. the result is highly consistent with the notion that the antibacterial activity of compounds 1 and 2 results from specific inhibition of Mvas. the experiment also suggests that inhibition of initial steps of the mevalonate pathway does not lead to buildup of toxic intermediates and that such inhibitors would likely be bacteriostatic rather than bacteriocidal antibiotics.
dIScuSSIon
there has been extensive debate on whether biochemical, target-based, or cellular phenotypic assays are more suitable for antibacterial lead discovery. engineered strains that allow the modulation of a target of interest offer a way to combine the advantages of both approaches (i.e., screening against a whole organism while biasing the hits toward a target of interest). thus far, such strategies have been limited to Moa studies of small compounds sets (e.g., subsequent to a phenotypic screen) or to the screening of small libraries. this is partly due to a complicated assay setup and challenges in compound logistics.
We have developed a simple, optical density-based assay relying on sensitized S. aureus strains that is fully compatible with high-density screening in a 1536-well format and that allowed testing of 1.3 million compounds within weeks. a particular difficulty of phenotypic antibacterial screens is that potentially interesting hits are hidden within a large number of undesired hits. the use of sensitized strains offers a particularly attractive diagnostic to distinguish specific inhibitors from unspecific growth inhibitors and nuisance hits. as discussed above, inhibitors of the target enzyme will appear more potent under low iPtG conditions, where a lower amount of enzyme is available to the bacteria, than under high iPtG conditions. this effect not only biases the hits toward specific inhibitors but can also be used as a diagnostic for specific inhibition because only the ic 50 of specific inhibitors should be sensitive to target modulation. two screens were run against four of six enzymes of the mevalonate pathway. We used mutant strains that placed the target enzymes hMG-coa synthase and the jointly regulated mevalonate kinase, mevalonate diphosphate decarboxylase, and phosphomevalonate kinase under the control of an iPtG-dependent promoter. assays were optimized and miniaturized to 384-well and 1536-well formats, which allowed screening of 1.3 million compounds. Both screens delivered high data quality as judged by Z′ statistics. this allowed a clear separation of hits from the null variation. screening at low iPtG conditions, weakly active inhibitors could be found that might be lost in the noise of a screen against wild-type S. aureus. specificity could then be tested by screening under different iPtG concentrations and detecting a shift of ic 50 for specific inhibitors, first in four and then in eight concentrations. for these steps, a high-performance compound logistics system was essential. the desire to run multiple rounds of cherry-picking in a short turnaround time, with concentrations and plate formats tailored to the experiment, put a large burden on compound logistics support. the flexibility offered by low-volume acoustic dispensing, implemented in a high-throughput cherry-picking system, 21 allowed us to repeatedly array >20 000 compounds in replicates and multiple concentrations in a matter of days. extensive profiling of hits could therefore be conducted. hits from both screens were tested in sensitized strains for all pathway enzymes, in the parental S. aureus strain as well as in the unrelated GlmU control strain. such profiling not only confirmed the Moa and established antibacterial activity against the wild-type strain but also allowed to test for synergistic hits that would inhibit multiple enzymes in the pathway. such dual inhibitors could be of great interest because they promise to reduce the risk of rapid resistance development.
it was critical to show that inhibitors of the sensitized strain would also be active in the wild-type organism. We used a standard broth micro-dilution assay to determine Mics of these compounds. in a panel of gram-positive and gram-negative FIg. 6. antibacterial activity of compounds 1 (c1) and 2 (c2) is reversed by the addition of mevalonate to the growth medium. hymeglusin (hym) is used as a positive control, and tetracycline (tet) is used as a negative control. addition of mevalonate, but not of the closely related compounds 3-hydroxymethylglutarate (hMG) or 2-hydroxymethylveleric acid (hMVa), to the agar medium reduced the inhibition zones of hymeglusin, compound 1, or compound 2 and had no effect on the inhibition zone of tetracycline. pathogens, potent antimicrobial activities were found against bacteria that use the mevalonate pathway, whereas no measurable antibacterial activity was found against bacteria that use other means to produce iPP. Mevalonate feeding rescued growth in these experiments, confirming pathway inhibition as a specific mode of action but also pointing to a bacteriostatic rather than bacteriocidal effect of such inhibitors. although bactericidal drugs seem inherently more attractive, many bacteriostatic agents are very successful drugs. examples of bacteriostatic antibiotics include tetracyclines, sulfonamides, trimethoprim, macrolides, and recently linezolid. it should also be noted that blocking the iPP biosynthesis pathway would likely result in a reduced production of certain virulence factors such as staphyloxanthin. 13 such an effect would facilitate clearance of bacterial infection by host innate immunity.
We have developed robust, high-density assays for mevalonate pathway enzymes using engineered S. aureus strains. these assays allowed the discovery of potent antibacterial leads that led to an active hit-to-lead program.
